Current Challenges Towards the Development of a Blood Test for Parkinson’s Disease

Diagnostics

Jose A. Santiago²  Judith A. Potashkin¹ 

[1] The Cellular and Molecular Pharmacology Department, The Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064-3037, USA; E-Mail

关键词: biomarkers;    blood;    Parkinson’s disease;   

DOI  :  10.3390/diagnostics4040153

来源: mdpi

【 摘 要 】

Parkinson’ disease (PD) is the second most prevalent neurodegenerative disease worldwide. To date, there is no disease-modifying agent, and current medical treatment only provides symptomatic benefits. Early diagnosis of PD would be useful in clinical practice to identify patients for clinical trials, test potential drugs and neuroprotective agents and track their therapeutic effect. Considerable progress has been made in the discovery and validation of diagnostic biomarkers for PD. In particular, blood-based biomarkers have shown promise in identifying PD patients in samples from independent clinical trials. Evaluation of these biomarkers in de novo patients and individuals at risk for PD remains a top priority. Here, we review the current advances and challenges toward the clinical translation of these biomarkers into a blood-based test for PD.

【 授权许可】

CC BY   
© 2014 by the authors; licensee MDPI, Basel, Switzerland.